BioNTech and Bristol Myers Squibb Form Strategic Partnership for Cancer Antibody Development

BioNTech和Bristol Myers Squibb宣布建立战略合作伙伴关系，共同开发和商业化癌症抗体候选药物BNT327，该交易潜在价值高达111亿美元。

关键事实

地区Germany

信号类型合作

up to $11.1 billionPotential value of the strategic partnership between BioNTech and Bristol Myers Squibb.

来源背景

BioNTech has entered into a strategic partnership with Bristol Myers Squibb to co-develop and commercialize BNT327, a bispecific antibody candidate for cancer treatment, in a deal valued at up to $11.1 billion.

阅读完整来源 →

频道背景

查看频道

健康科技与生物技术

此信号属于健康科技与生物技术频道。浏览相关信号，了解此发展如何融入更广泛的行业格局。

115 条频道信号

我的笔记

登录后可保存信号笔记。